The new equivocal

Changes to HER2 FISH results when applying the 2013 ASCO/CAP guidelines

Thomas H. Long, Helen Lawce, Connie Durum, Stephen Moore, Susan Olson, Ken Gatter, Megan Troxell

Research output: Contribution to journalArticle

41 Citations (Scopus)

Abstract

Objectives: Human epidermal growth factor receptor 2 (HER2, ERBB2) testing is an important prognostic/predictive marker in breast cancer management, especially in selecting HER2-targeted treatment. American Society of Clinical Oncology (ASCO)/College of American Pathologists (CAP) guidelines address HER2 status and were recently revised in 2013, replacing the 2007 version. For in situ hybridization interpretation, 2013 guidelines return to the prior threshold of a HER2/CEP17 ratio of 2.0 or greater for positive and eliminate 1.8 to 2.2 as the equivocal range. Also, the HER2 signal/nucleus ratio is accounted for, with 6.0 or greater for positive and 4.0 to less than 6.0 for equivocal, even in cases with a HER2/CEP17 ratio less than 2.0. Methods: With institutional review board approval, we reviewed our 2006 to 2012 HER2 fluorescence in situ hybridization (FISH) results and classified them according to both the 2007 and 2013 guidelines as negative, positive, or equivocal. Results: Of 717 HER2 FISH results, 55 (7.7%) changed category when reassessed by 2013 guidelines. Nineteen of 25 results in the 2007 equivocal category were reassigned as positive (n = 13) or negative (n = 6). Thirty-five previously negative cases became equivocal in the 2013 scheme, 12 of these with 1+ immunohistochemistry. The positive category increased from 71 to 85. Conclusions: The 2013 ASCO/CAP guidelines increased the number of HER2 FISH positive and equivocal results. The equivocal group is substantially different, posing a dilemma for clinical management.

Original languageEnglish (US)
Pages (from-to)253-262
Number of pages10
JournalAmerican Journal of Clinical Pathology
Volume144
Issue number2
DOIs
StatePublished - Aug 1 2015

Fingerprint

Medical Oncology
Fluorescence In Situ Hybridization
Guidelines
Research Ethics Committees
In Situ Hybridization
Immunohistochemistry
Pathologists
Breast Neoplasms

Keywords

  • ASCO/CAP guidelines
  • ERBB2
  • Fluorescence in situ hybridization
  • HER2
  • Human epidermal growth factor receptor

ASJC Scopus subject areas

  • Pathology and Forensic Medicine
  • Medicine(all)

Cite this

The new equivocal : Changes to HER2 FISH results when applying the 2013 ASCO/CAP guidelines. / Long, Thomas H.; Lawce, Helen; Durum, Connie; Moore, Stephen; Olson, Susan; Gatter, Ken; Troxell, Megan.

In: American Journal of Clinical Pathology, Vol. 144, No. 2, 01.08.2015, p. 253-262.

Research output: Contribution to journalArticle

@article{44a321eb5d634e01921bf28cc66a6971,
title = "The new equivocal: Changes to HER2 FISH results when applying the 2013 ASCO/CAP guidelines",
abstract = "Objectives: Human epidermal growth factor receptor 2 (HER2, ERBB2) testing is an important prognostic/predictive marker in breast cancer management, especially in selecting HER2-targeted treatment. American Society of Clinical Oncology (ASCO)/College of American Pathologists (CAP) guidelines address HER2 status and were recently revised in 2013, replacing the 2007 version. For in situ hybridization interpretation, 2013 guidelines return to the prior threshold of a HER2/CEP17 ratio of 2.0 or greater for positive and eliminate 1.8 to 2.2 as the equivocal range. Also, the HER2 signal/nucleus ratio is accounted for, with 6.0 or greater for positive and 4.0 to less than 6.0 for equivocal, even in cases with a HER2/CEP17 ratio less than 2.0. Methods: With institutional review board approval, we reviewed our 2006 to 2012 HER2 fluorescence in situ hybridization (FISH) results and classified them according to both the 2007 and 2013 guidelines as negative, positive, or equivocal. Results: Of 717 HER2 FISH results, 55 (7.7{\%}) changed category when reassessed by 2013 guidelines. Nineteen of 25 results in the 2007 equivocal category were reassigned as positive (n = 13) or negative (n = 6). Thirty-five previously negative cases became equivocal in the 2013 scheme, 12 of these with 1+ immunohistochemistry. The positive category increased from 71 to 85. Conclusions: The 2013 ASCO/CAP guidelines increased the number of HER2 FISH positive and equivocal results. The equivocal group is substantially different, posing a dilemma for clinical management.",
keywords = "ASCO/CAP guidelines, ERBB2, Fluorescence in situ hybridization, HER2, Human epidermal growth factor receptor",
author = "Long, {Thomas H.} and Helen Lawce and Connie Durum and Stephen Moore and Susan Olson and Ken Gatter and Megan Troxell",
year = "2015",
month = "8",
day = "1",
doi = "10.1309/AJCP3Q9WFOQTKUVV",
language = "English (US)",
volume = "144",
pages = "253--262",
journal = "American Journal of Clinical Pathology",
issn = "0002-9173",
publisher = "American Society of Clinical Pathologists",
number = "2",

}

TY - JOUR

T1 - The new equivocal

T2 - Changes to HER2 FISH results when applying the 2013 ASCO/CAP guidelines

AU - Long, Thomas H.

AU - Lawce, Helen

AU - Durum, Connie

AU - Moore, Stephen

AU - Olson, Susan

AU - Gatter, Ken

AU - Troxell, Megan

PY - 2015/8/1

Y1 - 2015/8/1

N2 - Objectives: Human epidermal growth factor receptor 2 (HER2, ERBB2) testing is an important prognostic/predictive marker in breast cancer management, especially in selecting HER2-targeted treatment. American Society of Clinical Oncology (ASCO)/College of American Pathologists (CAP) guidelines address HER2 status and were recently revised in 2013, replacing the 2007 version. For in situ hybridization interpretation, 2013 guidelines return to the prior threshold of a HER2/CEP17 ratio of 2.0 or greater for positive and eliminate 1.8 to 2.2 as the equivocal range. Also, the HER2 signal/nucleus ratio is accounted for, with 6.0 or greater for positive and 4.0 to less than 6.0 for equivocal, even in cases with a HER2/CEP17 ratio less than 2.0. Methods: With institutional review board approval, we reviewed our 2006 to 2012 HER2 fluorescence in situ hybridization (FISH) results and classified them according to both the 2007 and 2013 guidelines as negative, positive, or equivocal. Results: Of 717 HER2 FISH results, 55 (7.7%) changed category when reassessed by 2013 guidelines. Nineteen of 25 results in the 2007 equivocal category were reassigned as positive (n = 13) or negative (n = 6). Thirty-five previously negative cases became equivocal in the 2013 scheme, 12 of these with 1+ immunohistochemistry. The positive category increased from 71 to 85. Conclusions: The 2013 ASCO/CAP guidelines increased the number of HER2 FISH positive and equivocal results. The equivocal group is substantially different, posing a dilemma for clinical management.

AB - Objectives: Human epidermal growth factor receptor 2 (HER2, ERBB2) testing is an important prognostic/predictive marker in breast cancer management, especially in selecting HER2-targeted treatment. American Society of Clinical Oncology (ASCO)/College of American Pathologists (CAP) guidelines address HER2 status and were recently revised in 2013, replacing the 2007 version. For in situ hybridization interpretation, 2013 guidelines return to the prior threshold of a HER2/CEP17 ratio of 2.0 or greater for positive and eliminate 1.8 to 2.2 as the equivocal range. Also, the HER2 signal/nucleus ratio is accounted for, with 6.0 or greater for positive and 4.0 to less than 6.0 for equivocal, even in cases with a HER2/CEP17 ratio less than 2.0. Methods: With institutional review board approval, we reviewed our 2006 to 2012 HER2 fluorescence in situ hybridization (FISH) results and classified them according to both the 2007 and 2013 guidelines as negative, positive, or equivocal. Results: Of 717 HER2 FISH results, 55 (7.7%) changed category when reassessed by 2013 guidelines. Nineteen of 25 results in the 2007 equivocal category were reassigned as positive (n = 13) or negative (n = 6). Thirty-five previously negative cases became equivocal in the 2013 scheme, 12 of these with 1+ immunohistochemistry. The positive category increased from 71 to 85. Conclusions: The 2013 ASCO/CAP guidelines increased the number of HER2 FISH positive and equivocal results. The equivocal group is substantially different, posing a dilemma for clinical management.

KW - ASCO/CAP guidelines

KW - ERBB2

KW - Fluorescence in situ hybridization

KW - HER2

KW - Human epidermal growth factor receptor

UR - http://www.scopus.com/inward/record.url?scp=84942636327&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84942636327&partnerID=8YFLogxK

U2 - 10.1309/AJCP3Q9WFOQTKUVV

DO - 10.1309/AJCP3Q9WFOQTKUVV

M3 - Article

VL - 144

SP - 253

EP - 262

JO - American Journal of Clinical Pathology

JF - American Journal of Clinical Pathology

SN - 0002-9173

IS - 2

ER -